WSC
ICPT

White Square Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

White Square Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-65,500
Closed -$7.12M – 10
2016
Q4 		$7.12M Buy
+65,500
New +$7.8M 11.05% 4

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

White Square Capital's ICPT Position: Q1 2017 in Review

White Square Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2017, closing a stake of 65,500 shares — an estimated $7.12M sold.

White Square Capital first reported a position in ICPT in Q4 2016 and held it in 1 quarter. The position peaked at $7.12M in Q4 2016. 150 funds tracked by Wall St. Rank hold ICPT as of Q1 2017.

  • White Square Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • White Square Capital sold 65,500 Intercept Pharmaceuticals, Inc. shares in Q1 2017, an estimated $7.12M.
  • White Square Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • White Square Capital's Intercept Pharmaceuticals, Inc. position peaked at $7.12M in Q4 2016.
  • 150 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2017.

Based on White Square Capital's 13F filing for Q1 2017, filed 12 May 2017.